The NICRF welcomes the first participants of the XanADu Study, December 2017

Professor Peter Passmore, Principal Investigator within the Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, QUB, is undertaking a Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 35mg Twice Daily Xanamem in Subjects with Mild Dementia due to Alzheimer's Disease (AD).

Read more about the XanADu Study here.